CalciMedica (CALC) announced a poster presentation titled, “Store-Operated Calcium-Channel Inhibitor Auxora Improves Kidney Function Following Ischemia-Induced AKI in Rats” at the American Society of ...

This technology has vast potential to help patients but remains underutilized and underappreciated. The tools are there. What’s lacking are harmonized controls, regulatory guidelines and database ...

Once thought to be a flaw in the system, new research suggests that CD4 T cells may actually hold the key to maintaining a ...

CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition ...

Inflammatory arthritis resulting from immune checkpoint inhibitor use is immunologically unique and likely driven by T cells ...

CalciMedica Inc. ("CalciMedica" or the "Company") , a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for ...

Urolithin A, a natural postbiotic known to trigger mitophagy, rejuvenated key immune cell functions in healthy middle-aged ...

FROM 27th September–1st October 2025, Amsterdam, the Netherlands, welcomed over 22,000 respiratory professionals to the ...

Background Globally, an estimated 296 million individuals live with chronic hepatitis B virus (HBV) infection, carrying ...

The implementation of VCE scoring in clinical practice could inform early pre-emptive therapeutic interventions, exclusively ...